Myelodysplastic syndromes: prognostic significance of multilineage dysplasia in patients with refractory anemia or refractory anemia with ringed sideroblasts

Abstract

by LIBS6 and fibrinogen, without affecting primary aggregation, although full irreversible aggregation was impaired. 1 But inhibition of full, irreversible aggregation by wortmannin did not impair thromboxane A 2 accumulation in response to LIBS6 plus fibrinogen. These data suggest that the close platelet-to-platelet contact that is brought about by platelet aggregation (primary or full) is not sufficient to generate thromboxane A 2 and depends on signaling from the ADP receptors. Hence we disagree with the interpretation of Cattaneo et al of the previously published results from several laboratories. We stand by our interpretation of our results that outside-in signaling from both the integrin ␣IIb␤3 and the P2 receptors is required for ADP-induced thromboxane A 2 generation in platelets. We agree with Cattaneo et al that ADP-induced thromboxane generation is greatly enhanced and can be seen in most healthy individuals when extracellular calcium is decreased to micromolar levels.

Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes

“…Several groups have since reported on the utility of this classification with the observation that RCMD is associated with a significantly poorer survival than RA. 4,5 Most patients with RA or RCMD have normal cytogenetics and in the absence of definitive biologic markers, early diagnosis or prognostic stratification of patients is currently not possible.…”

The WHO classification of MDS does make a difference

“…Others uphold its usefulness. 12,19,20 Treatment of MDS varies considerably between the different subclasses and risk groups. Although only a minority of patients are eligible for curative approaches, the possibilities to relieve cytopenia in particular, with proerythroid growth factor treatment, are gradually improving.…”

The Search for Better Prognostic Models in Myelodysplastic Syndromes

“…Median survival with RCMD (24 months) was intermediate between survival with RA/RARS (108 months) and survival with RAEB (18 months). Other reports have confirmed the impact of severe dysplasia on the outcome of patients with MDS [18, 19]. …”